[ad_1]
The Montreal COLCORONA clinical trial will continue its third phase following encouraging preliminary results to treat people with COVID-19.
• Read also: COVID-19: 1,395 new cases and 12 more deaths in Quebec
• Read also: All the developments in the COVID-19 pandemic
The Montreal Heart Institute (MHI) said in a statement Sunday that the continued recruitment of outpatient adult patients with COVID-19 has been authorized following a recommendation from the independent data monitoring committee following the second interim analysis of the study.
“We aim to complete patient recruitment in this large study within the next month and hope that colchicine will reduce the risk of complications from COVID-19,” said Dr.r Jean-Claude Tardif, director of the ICM Research Center, professor of medicine at the University of Montreal and principal investigator of the COLCORONA study.
This initiative aims to find out if colchicine can prevent the risk of serious complications from COVID-19. The Montreal Heart Institute clarified that “this is one of the few large-scale COVID-19 studies that outpatients can participate in.”
Contactless, as it is done at home for patients with the disease who do not need to be hospitalized, this study was conducted in Canada, the United States, Europe, South America and Africa. from the south.
“With the dramatic increase in COVID-19 cases around the world, it becomes even more critical to continue seeking treatments that can not only improve the situation of people hospitalized with severe complications, but those with symptoms are also less severe and may stay on. home, “said Dr.r Jean-Claude Tardif.
COLCORONA is funded by the government of Quebec, the National Heart, Lung, and Blood Institute of the United States, and the Bill & Melinda Gates Foundation. The companies CGI, Dacima and Pharmascience are also working together.
Healthcare professionals and COVID-19 patients who wish to participate can request information by calling 1 877 536-6837.
Source link
